Trexquant Investment LP Has $17.58 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Trexquant Investment LP trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 45.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 226,020 shares of the medical device company’s stock after selling 190,493 shares during the period. Trexquant Investment LP’s holdings in DexCom were worth $17,578,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Norges Bank bought a new position in DexCom in the 4th quarter worth $385,367,000. Congress Asset Management Co. grew its position in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD bought a new position in shares of DexCom in the fourth quarter worth about $96,507,000. Two Sigma Advisers LP lifted its position in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after purchasing an additional 739,000 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Stock Down 1.4 %

Shares of NASDAQ DXCM opened at $67.32 on Wednesday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $141.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $26.31 billion, a P/E ratio of 47.08, a P/E/G ratio of 2.30 and a beta of 1.28. The firm has a 50 day moving average price of $81.62 and a 200 day moving average price of $77.11.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on DXCM. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Cfra Research upgraded shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.